Device and pharmaceutical company Angiotech Pharmaceuticals (Vancouver, British Columbia) has made good on what it promised early last year: to file for FDA clearance of its anti-infective 5-Fluorouracil-coated (5-FU) Central Venous Catheter (CVC) before year's end.

Cancer drug is used by Angiotech as new CVC anti-infective

Name: Relias Media
Price range: $

January 2, 2015

Reprints

Recognizing, Managing, and Reporting Pediatric Sexual Abuse and Assault
Eleventh Circuit Affirms Jury Verdict of $2.5 Million for Mesh Device Plaintiff Despite Close Call on Statute of Limitations
Indiana Appellate Court Allows Case to Proceed Against Doctor Accused of Improperly Accessing Patients’ Medical Records
Malpractice Insurance Rates Increasing After Stable Period
Clinical Decision Software Highly Effective in OR